In March, two biotechnology companies were given the greenlight by the Food and Drug Administration, or FDA, to conduct ...

Study Finds Chemotherapy Antidote Could Improve Recovery After Chemotherapy-Induced Kidney Toxicity Jan. 6, 2025 — An FDA-approved ... Worsening of Chronic Kidney Disease Sep. 12, 2024 ...

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

Novartis NVS obtains FDA ... disease progression. The approval was granted on an accelerated basis. The candidate got approval under the brand name Vanrafia. IgAN is a progressive, rare kidney ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...

University of Pittsburgh Medical School researchers walk us through multiple approaches they’ve tried in the past, are currently using or plan to use in the future, as well as the significant ...

The FDA has granted Priority Review to pegcetacoplan for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

UCLA researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker ...